Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival

References

• Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. British Journal of Haematology 2001; 113: 265–274
   PubMed Web of Science ®Google Scholar
• Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–239
   PubMed Web of Science ®Google Scholar
• Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. The Journal of Biological Chemistry 1992; 267: 10709–10715
   PubMed Web of Science ®Google Scholar
• Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449–1456
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. The EMBO Journal 1995; 14: 1129–1135
   PubMed Web of Science ®Google Scholar
• Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal end neoplastic cells. Laboratory Investigation 1993; 69: 415–429
   PubMed Web of Science ®Google Scholar
• Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, et al. Expression of the Fas ligand in cells of T cell lineage. Journal of Immunology 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Glass A, Walsh C M, Lynch D H, Clark W R. Regulation of the Fas lytic pathway in cloned CTL. Journal of Immunology 1996; 156: 3638–3644
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan C I, Copeland N G, Jenkins N A, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka M, Brannan C I, Jenkins N A, Copeland N G, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976
   PubMed Web of Science ®Google Scholar
• Müschen M, Rajewsky K, Krönkr M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Modern Trends in Immunology 2002; 23: 75–80
   Google Scholar
• Vignaux F, Golstein P. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway. European Journal of Immunology 1994; 24: 923–927
   PubMed Web of Science ®Google Scholar
• Alderson M R, Tough T W, Davis-Smith T, Braddy S, Falk B, Schooley K A, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. The Journal of Experimental Medicine 1995; 181: 71–77
   PubMed Web of Science ®Google Scholar
• Lynch D H, Ransdell F, Alderson M R. Fas and Fas-L in the homeostatic regulation of immune responses. Immunology Today 1995; 16: 569–574
   PubMedGoogle Scholar
• Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–530
   PubMed Web of Science ®Google Scholar
• Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650–652
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani S M, Weller M, et al. Local Fas/Apo-1 (CD95) ligand-mediated tumor cell killing in vivo. European Journal of Immunology 1995; 25: 2253–2258
   PubMed Web of Science ®Google Scholar
• Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke R C. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630–632
   PubMed Web of Science ®Google Scholar
• Sugihara A, Saiki S, Tsuji M, Tsujimura T, Nakata Y, Kubota A, et al. Expression of Fas and Fas ligand in testis and testicular germ cell tumors: an immunohistochemical study. Anticancer Research 1997; 17: 3861–3865
   PubMed Web of Science ®Google Scholar
• Griffith T S, Brunner T, Fletcher S M, Gren D R, Ferguson T A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189–1192
   PubMed Web of Science ®Google Scholar
• Hunt J S, Vassmer D, Ferguson T A, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leucocytes between the mother and the conceptus. Journal of Immunology 1997; 158: 4122–4128
   PubMed Web of Science ®Google Scholar
• Griffith T S, Ferguson T A. The role of Fas-L-induced apoptosis in immune privilege. Immunology Today 1997; 18: 240–244
   PubMedGoogle Scholar
• Green D R, Ware C F. Fas-ligand: privilege and peril. Proceedings of the National Academy of Sciences (USA) 1997; 94: 5986–5990
   PubMed Web of Science ®Google Scholar
• Badley A D, McElhinny J A, Leibson P J, Lynch D H, Alderson M R, Paya C V. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Journal of Virology 1996; 70: 199–206
   PubMed Web of Science ®Google Scholar
• Liles W C, Kiener P A, Ledbetter J A, Aruffo A, Klebanoff S J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. The Journal of Experimental Medicine 1996; 184: 429–440
   PubMed Web of Science ®Google Scholar
• Kondo E, Yoshino T, Nishiuchi R, Sakuma I, Nishizaki K, Kayagaki N, et al. Expression of Fas ligand mRNA in germinal centers of the human tonsil. Journal of Pathology 1997; 183: 75–79
   PubMed Web of Science ®Google Scholar
• Sträter J, Mariani S M, Walczak H, Rucker F G, Leithauser F, Krammer P H, Moller P. CD95 Ligand (CD95L) in normal lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. American Journal of Pathology 1999; 154: 193–201
   PubMed Web of Science ®Google Scholar
• Leithauser F, Dhein J, Merchtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Laboratory Investigation 1993; 69: 415–429
   PubMed Web of Science ®Google Scholar
• Müschen M, Warskulat U, Beckmann M W. Defining CD95 as a tumor suppressor gene. Journal of Molecular Medicine 2000; 78: 312–325
   PubMed Web of Science ®Google Scholar
• Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann M W. CD95-ligand expression as a mechanism of immune escape in breast cancer. Acta Microbiologica et Immunologica Hungarica 2000; 99: 69–77
   Google Scholar
• Müschen M, Warskulat U, Schmidt B, Schulz W A, Haussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon γ and all-trans retinoic acid. Biological Chemistry 1998; 379: 1083–1091
   PubMed Web of Science ®Google Scholar
• Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French L E, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363–1366
   PubMed Web of Science ®Google Scholar
• O'Connell J, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. The Journal of Experimental Medicine 1996; 184: 1075–1082
   PubMed Web of Science ®Google Scholar
• Nonomura N, Mili T, Yokoyama M. Fas/APO-1 mediated apoptosis of human renal cell carcinoma. Biochemical and Biophysical Research Communications 1996; 225: 945–951
   Web of Science ®Google Scholar
• Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nature Medicine 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• Saas P, Walker P R, Hahne M, Quiquerez A L, Schnuriger V, Perin G, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. The Journal of Clinical Investigation 1997; 99: 1173–1178
   PubMed Web of Science ®Google Scholar
• Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression in human esophageal cancer. Cancer Research 1998; 58: 2057–2062
   PubMed Web of Science ®Google Scholar
• Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. The Journal of Pathology 2000; 190: 20–30
   PubMed Web of Science ®Google Scholar
• Jiang J, Ulbright T M, Zhang S, Eckert G J, Kao C, Gardner T A, et al. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer 2002; 95: 296–300
   PubMed Web of Science ®Google Scholar
• Walker P R, Saas P, Dietrich P Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. Journal of Immunology 1997; 158: 4521–4524
   PubMed Web of Science ®Google Scholar
• Westendorf J J, Lammert J M, Jelinek D F. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85: 3566–3576
   PubMed Web of Science ®Google Scholar
• Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, et al. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86: 1939–1945
   PubMed Web of Science ®Google Scholar
• Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757–764
   PubMed Web of Science ®Google Scholar
• Shain K H, Landowski T H, Buyuksal I, Cantor A B, Dalton W S. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000; 14: 830–840
   PubMed Web of Science ®Google Scholar
• Tu Y, Xu F H, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805–1812
   PubMed Web of Science ®Google Scholar
• Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89: 227–234
   PubMed Web of Science ®Google Scholar
• Frassanito M A, Silvestris F, Silvestris N, Cafforio P, Camarda G, Iodice G, Dammacco F. Fas/Fas ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology 1998; 114: 179–188
   PubMed Web of Science ®Google Scholar
• Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 1995; 85: 3679–3687
   PubMed Web of Science ®Google Scholar
• Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12–20
   PubMed Web of Science ®Google Scholar
• Greil R, Egle A, Villunger A. On the role and significance of Fas (Apo-1/CD95) ligand (Fas-L) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Leukemia and Lymphoma 1998; 31: 477–490
   PubMed Web of Science ®Google Scholar
• Dai C H, Price J O, Brunner T, Krantz S B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon-γ to produce erythroid cell apoptosis. Blood 1998; 91: 1235–1241
   PubMed Web of Science ®Google Scholar
• De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999; 93: 796–803
   PubMed Web of Science ®Google Scholar
• Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2001; 97: 1155–1164
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L-positive/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002; 99: 1305–1313
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Grinello D, Dammacco F. Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma. Reviews in Clinical and Experimental Hematology 2002; 6(Suppl 1)39–46
   Google Scholar
• Tucci M, Grinello D, Cafforio P, Silvestris F, Dammacco F. Anemia in multiple myeloma: role of deregulated plasma cell apoptosis. Leukemia and Lymphoma 2002; 43: 1527–1533
   PubMed Web of Science ®Google Scholar
• Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004; 18: 1176–1199
   PubMed Web of Science ®Google Scholar
• Nakashima T, Sasaki H, Tsuboi M, Kawakami A, Fujiyama K, Kiriyama T, et al. Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 1998; 139: 2032–2040
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. British Journal of Haematology 2003; 122: 39–52
   PubMed Web of Science ®Google Scholar
• Kanda Y, Ara C, Chizuka A, Yamamoto R, Hamaki T, Suguro M, et al. Lack of correlation between clinical characteristics and serum soluble Fas ligand levels in patients with multiple myeloma. Leukemia and Lymphoma 2001; 40: 351–356
   PubMed Web of Science ®Google Scholar
• Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, et al. Activated B cells express functional Fas ligand. European Journal of Immunology 1996; 26: 721–724
   PubMed Web of Science ®Google Scholar
• Landowski T H, Gleason-Guzman M C, Dalton W S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854–1861
   PubMed Web of Science ®Google Scholar
• Landowski T H, Shain K H, Oshiro M M, Buyuksal I, Painter J S, Dalton W S. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood 1999; 94: 265–274
   PubMed Web of Science ®Google Scholar
• Dimberg L Y, Dimberg A I, Ivarsson K, Stromberg T, Osterborg A, Nilsson K, et al. Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 2005; 106: 1346–1354
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. The New England Journal of Medicine 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar